N Engl J Med 391(2):109121 De Nicola L, Cozzolino M, Genovesi S et al (2022) Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease
[1] This potential selectivity is attributed to the fact that Ipamorelin does not appear, in any way, to affect the secretion of other pituitary hormones
These enzymes are broadly distributed in various tissues (brain, lungs, kidneys), T-cell, B-cell and natural killer cells (Lambeir et al., 2003)
A novel dual GIPGLP1 receptor agonist, tirzepatide, is currently under development for the treatment of type 2 diabetes mellitus (T2DM)
While their names are nearly identical, their roles are distinct
It targets the biological root of hair thinning, not just the symptoms, at the follicle level